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ABSTRACT:
To understand how non-malignant human mammary epithelial cells (HMEC) transit from a disorganized proliferating to an organized growth arrested state, and to relate this process to the changes that occur in breast cancer, we studied gene expression changes in non-malignant HMEC grown in three-dimensional cultures, and in a previously published panel of microarray data for 295 breast cancer samples. We hypothesized that the gene expression pattern of organized and growth arrested mammary acini would share similarities with breast tumors with good prognoses. Using Affymetrix HG-U133A microarrays, we analyzed the expression of 22,283 gene transcripts in two HMEC cell lines, 184 (finite life span) and HMT3522 S1 (immortal non-malignant), on successive days post-seeding in a laminin-rich extracellular matrix assay. Both HMECs underwent growth arrest in G0/G1 and differentiated into polarized acini between days 5 and 7. We identified gene expression changes with the same temporal pattern in both lines. We show that genes that are significantly lower in the organized, growth arrested HMEC than in their proliferating counterparts can be used to classify breast cancer patients into poor and good prognosis groups with high accuracy. This study represents a novel unsupervised approach to identifying breast cancer markers that may be of use clinically.
INTRODUCTION:
Loss of growth control and disruption of tissue architecture are among the earliest hallmarks of cancer. We hypothesized that the gene expression changes that occur during the organization and growth arrest of cultured mammary acini would share similarities with breast tumors that had a good prognosis. To test this hypothesis, we examined temporal changes in gene expression in two non-malignant human mammary epithelial cells (HMEC) grown in a three-dimensional laminin-rich extracellular matrix (3D lrECM) assay (1) . In this model, single non-malignant breast epithelial cells form polarized growth arrested multicellular structures that resemble acini over a period of several days. This transition from the unpolarized actively dividing state to a polarized non-dividing state is the reverse of what happens in the early stages of tumorigenesis.
We used two non-malignant HMEC, a non-immortalized HMEC strain,184 (2, 3) , and spontaneously immortalized cell line, HMT3522-S1 (4) , and monitored the changes in gene and protein expression as the cells formed acinar structures in 3D lrECM cultures. During the process of self-organization and withdrawal from the cell cycle, we noted a progressive hypophosphorylation of the retinoblastoma gene product (Rb) and an induction of the cyclin-dependent kinase (cdk) inhibitor p27 kip1 . Analysis of the changes in gene expression in both cell lines allowed the identification of sets of commonly regulated genes.
While established breast cancer prognostic markers such as tumor size, grade, lymph node and hormone receptor status are useful in predicting survival in large populations (5) (6) (7) , there is a pressing need to develop better prognostic signatures to predict recurrence and overall survival. A particular benefit would be the identification of patients with good prognoses whose tumors are highly unlikely to recur and who nevertheless are being treated with cytotoxic chemotherapies (8) . The advent of gene expression technologies has greatly aided the identification of molecular signatures with value for tumor classification and prognosis prediction (9) (10) (11) (12) (13) (14) . Van (17) . In each of these studies, the predictive signatures have been derived by using a training set of patients of known outcome, followed by testing these signatures in a validation set of patients. In contrast, our approach has been to identify directly the genes whose expression changes as cultured mammary epithelial cells transition from a disorganized to an organized state, and to then test as proof of principle the possible utility of these genes as prognostic markers in a validation set of patients.
MATERIALS AND METHODS:
Cell Culture.
Finite-lifespan 184 HMEC were obtained from reduction mammoplasty tissue and grown in a serum-free MCDB 170 medium (MEGM; Clonetics Division of BioWhittaker, Walkersville, MD, USA), as described previously (2, 18) . HMT-3522 S1
mammary epithelial cells were cultured in H14 medium (DMEM/F12 containing 250 ng/ml insulin, 10 µg/ml transferrin, 2.6 ng/ml sodium selenite, 10 -10 M estradiol, 1.4 x 10 -6 M hydrocortisone, 10 ng/ml EGF and 5 µg /ml prolactin). The cells were cultured in a 6 3D laminin-rich extracellular matrix (Matrigel, BD Biosciences), as described (19 individual marker genes, the patients were stratified into quartiles for expression of each marker, and the survival curves were computed using the method of Kaplan and Meier.
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Statistical significance was determined using the log-rank test. Statistical analyses were performed using Graphpad Prism. For survival analysis of the set of 249 marker genes, the patients were stratified into two groups using GeneSpring software by hierarchical cluster analysis with a distance metric of the expression pattern of all 249 genes. KaplanMeier survival curves, log-rank statistics, and the estimated hazard ratio for these two groups were computed using the Excel add-in EcStat.
Microarray hybridization and analysis.
Cell samples were harvested in duplicate at three time points, 3, 5, and 7 days, after seeding in lrECM. Purified total cellular RNA was biotin-labeled and hybridized to human oligonucleotide microarrays (Affymetrix HG-U133A), as previously described Figure 1D ). Cyclins D1, E, and A, as well as their binding partners-cdks 4, 6, and 2-also decreased during this period (data not shown). In contrast, the cdk inhibitor p27 kip1 increased between days 5 and 10 ( Figure 1D ). The pronounced down-modulation of Rb phosphorylation and the elevation of p27 kip1 protein levels were changes observed in both the S1 and 184 cells (data not shown). Although other studies have used different HMEC (MCF10A) to determine how cells can escape normal growth control (23) (24) (25) (26) , the mechanisms by which mammary cells actually initiate and maintain growth arrest during the process of acini formation in the context of 3D-lrECM remain to be determined.
Global gene expression analysis of the time course of HMECs in 3D.
To probe systematically the molecular changes that accompany acinus formation, we analyzed the expression profiles of 22,283 transcripts using Affymetrix HG-U133A microarrays. Microarray experiments were performed with biological duplicates using RNA samples harvested from S1 and 184 cells, after 3, 5, and 7 days' culture in lrECM.
Since growth arrest and polarization occurred with similar kinetics in both cell types ( Figure 3A) , we reasoned that the gene expression changes important for these processes would follow a common temporal pattern in both cell lines, and that changes that were cell type-specific could be disregarded.
We first identified genes that showed at least 1.5-fold changes during the time course in the individual cell specimens (ANOVA, p < 0.05) (within this window, 363
genes were up-regulated and 117 genes down-regulated in 184 cells; 234 genes were upregulated and 351 genes down-regulated in S1 cells). We then divided these lists into genes whose expression changed 'early' by our definition (between days 3 and 5) or 'late' (between days 5 and 7) in S1 and 184. Finally, we identified the genes from each temporal group that were common to both cell types ( Figure 2 ). A total of 60 genes with common temporal patterns were identified, including 21 genes that were up-regulated early, 11 genes that were up-regulated late, 6 genes that were down-regulated early, and 22 genes that were down-regulated late ( Figure 3B and 3C and supplementary material).
Correlation of the differentially expressed genes with survival of breast cancer patients.
To relate the process of acinar development in 3D lrECM cell cultures to the changes that occur in breast cancer, we examined the expression levels of the differentially regulated genes identified using our model using previously published microarray data for a panel of 295 breast cancer samples from the fresh-frozen-tissue bank of the Netherlands Cancer Institute, including 151 lymph node-negative and 144 lymph node-positive patient samples (15) . Fifty five of the 60 genes selected in our 3D culture analysis were included on these microarrays. We looked at 5-and 10-year survival data and applied Student's t-test to determine how many of the genes modulated in 3D cultures showed survival-associated expression changes. T-tests were performed to determine whether the difference in the expression level of a given gene in two groups (e.g., patients who survived five years versus patients who did not) was large enough that it was not likely to be due to chance. The numbers and percentages of genes exhibiting significantly different expression in the tumors of patients with differential survival (p < 0.05) were tabulated for a) all the genes represented on the microarrays, b) genes selected on the basis of differential expression during the 3D lrECM timecourse, or c) randomly generated gene lists ( Table 1 Collective gene signatures have the potential to discriminate among clinical endpoints more accurately than markers used individually. Hence, we tested the ability of our set of 19 genes to classify breast cancer patients into prognostic groups. We used hierarchical cluster analysis to separate the patients into groups and then determined the overall 10-year survival rates for these groups ( Figure 5 ). The cluster analysis separated the patients into five groups, three of which had tumors that expressed comparatively lower levels of most of the 19 genes, and two of which expressed higher levels. The 10-year survival rates for these 5 groups were 95, 84, 67, 61, and 54% respectively.
To test whether other sets of genes down-regulated late in the lrECM timecourse identified by using other selection strategies would also include useful breast cancer markers, we applied a second selection strategy ( Figure 6A ) and tested the ability of the resulting gene set to predict breast cancer prognosis. This second method was less restrictive than the first, and resulted in the identification of 287 genes that were significantly down-regulated late in the 3D time course of both HMEC specimens (for complete gene list and gene expression information, see supplemental information).
Seventeen of the 22 genes selected using Method 1 were also included in the 287 genes selected using Method 2. We tested the ability of these genes to predict breast cancer prognosis by using hierarchical cluster analysis in the same set of previously published microarray data from 295 breast cancers (15) . A large majority, 249 of the 287 genes were included on these microarrays. Of the 17 overlapping (methods 1 and 2) genes on the Affymetrix chips, 15 were present on the Rossetta chips: ACTB, ACTN1, CDK3, CKS2, DUSP4, EPHA2, HBP17, FOXM1, ODC1, RRM2, STK6, TNFRSF6B, TRIP13, TUBG1, VRK1.
Hierarchical cluster analysis using the 249 gene signature classified the samples into two groups of approximately equal numbers of tumors ( Figure 6B ). Overall 10 year survival rates were 90% (138 of 154) for the good prognosis group and 59% (83 of 141)
for the poor prognosis group. To assess the significance of these predictions and take into account patients that could not be followed the entire length of the study, we performed a Kaplan-Meier analysis. The results show that the 249 gene profile was highly informative in identifying patients with poor outcome (log rank p = 2.7x10 -10 ) ( Figure 6C ). The estimated hazard ratio for poor outcome (failure to survive) in the group with the poor prognosis signature as compared with the good prognosis signature was 4.7 [95% confidence interval 2.8 -7.9].
DISCUSSION:
Three-dimensional (3D) laminin-rich (lrECM) cultures permit non-malignant cells to exhibit self-organizing properties. Such cultures provide models that allow the study of processes that are aberrant in breast cancer (1, 19, 27, 28 Our approach represents a new way to identify genome-wide cancer prognostic markers. We based all the marker selection steps on HMEC cultured in 3D lrECM. The 3D model system provided a means to focus on epithelial cells themselves, and a defined, highly relevant biological process -the formation of breast acini. Whereas the stroma is absent, the 3D lrECM assays appears to substitute for myoepithelial cells and other signals that are needed to form an organized acini (29) . Differentially expressed genes identified using this model system are likely to be functionally linked to the transformation-relevant process. Further, we have applied an unsupervised method (hierarchical cluster analysis) to classify the patient samples using selected markers.
Hence, neither our method of marker selection nor our sample classification method relies on any clinical information.
Gene-expression profiling of tumors using DNA microarrays is a promising method for predicting prognosis and treatment response in cancer patients (17, (30) (31) (32) .
Two studies have recently employed genome-wide microarray analysis to identify gene signatures that predict prognosis in breast cancer. The profiles studied by both groups of researchers were reported to be more powerful predictors of the outcome of disease than standard systems based on clinical and histological criteria. The study by van't Veer et al. . In addition to cell-cycle genes, our prognostic genes also encoded products with other functions, including genes involved in cytoskeletal regulation (ACTB, ACTN1) (37), cell survival (TNFRSF6B) (38, 39) , polyamine biosynthesis (ODC1) (40) , and cell-cell interactions (EPHA2) (41) .
The genes in these additional functional groups were important in subdividing the patients into subgroups with differing survival rates.
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In conclusion, we report that the gene expression changes that commonly occur in non-malignant HMEC grown in 3D lrECM cultures provide gene expression signatures that effectively stratify patients into prognostic groups according to overall survival rates.
Our 249 gene signature achieved a hazard ratio of 4.7, which is comparable to hazard ratios achieved by large scale supervised breast cancer microarray studies. Our results underscore the relevance of 3D lrECM cultures for studies of malignant transformation, and suggest potentially valuable new biomarkers for further clinical evaluation.
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